Clinical trials: Uterine Neoplasm
Cancer of the Endometrium
Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer
The use of robotic surgery in the management of gynecologic cancers has increased exponentially in the United States since the implementation of technology in 2005.
- Trial name
- GOC2 (NCT01480999)
- Where
- 7 sites in Canada
- Volunteers
- 550 people
- Sponsor
- University Health Network, Toronto
Uterine Fibroids
Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis
A prospective non-randomized open label clinical trial to research the efficacy and safety of sirolimus in patients with symptomatic, recurrent uterine fibroids or/and various rare leiomyoma.
- Trial name
- NCT03500367
- Testing
- rapamycin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Cervical Intraepithelial Neoplasia
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL.
- Trial name
- NCT01880411
- Testing
- PEK Fusion Protein Vaccine
- Volunteers
- 15 people
- Sponsor
- HealthBanks Biotech Co., Ltd.
Cervical Cancer
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00057928
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 106 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Cervical Cancer
Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer
To evaluated the efficacy and safety of caldonirimab plus nimotuzumab as second-line or later therapy for recurrent or metastatic cervical cancer
- Trial name
- GCR-05 (NCT05606263)
- Testing
- Caldonirimab and Nimotuzumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Xi'an Jiaotong University
Metastatic Cancer, Endometrium Cancer
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for…
- Conditions
- Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
- Trial name
- NCT05036681
- Testing
- Futibatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come…
- Trial name
- innovaTV 301 (NCT04697628)
- Testing
- tisotumab vedotin, topotecan, vinorelbine
- Where
- 211 sites in United States, Argentina and 23 more
- Volunteers
- 502 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Fibroid Uterus
Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial
This study aims to investigate the efficacy of temporary clipping of the uterine artery and utero-ovarian ligament during robotically assisted myomectomy (RAM) for uterine fibroids.
- Trial name
- TACROM (NCT06269809)
- Testing
- Temporary clipping of the uterine arteries and the utero-ovarian ligmants., No temporary clipping of the uterine arteries and the utero-ovarian ligmants.
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 82 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of ADRX-0706 in Select Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
- Conditions
- Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
- Trial name
- NCT06036121
- Testing
- ADRX-0706
- Where
- 21 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Adcentrx Therapeutics
Solid Tumors, Carcinoma
Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
This study aims to evaluate the performance of a novel SPECT imaging agent, 111In-TJD-31, which targets placental alkaline phosphatase (ALPP).
- Conditions
- Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant
- Trial name
- NCT07815951
- Testing
- 111In-TJD-31 Injection
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yong He
Leiomyoma, Uterine Fibroids
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST (NCT00768742)
- Testing
- VizAblate Intrauterine Ultrasound-Guided RF Ablation
- Where
- 3 sites in Canada
- Sponsor
- Gynesonics
Endometrial Neoplasms, Neoplasms
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386…
- Conditions
- Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT04008797
- Testing
- E7386, Lenvatinib, Doxorubicin
- Where
- 106 sites in United States, Canada and 8 more
- Volunteers
- 301 people
- Sponsor
- Eisai Inc.
Cervix Cancer
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
- Trial name
- NCT00251888
- Testing
- campto (irinotecan), cisplatin (cisplatyl)
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- ARCAGY/ GINECO GROUP
Cervical Carcinoma, Fallopian Tube Carcinoma
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for…
- Conditions
- Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm
- Trial name
- NCT06492070
- Testing
- Best Practice, Cilostazol, Cryocompression Therapy
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Postmenopausal Bleeding, Endometrial Cancer
Performance of Ultrasound in Women With Postmenopausal or Abnormal Uterine Bleeding Between White and Black Ethnic Groups- a Retrospective Cohort Study.
Primary Objective: To assess whether there is a higher incidence of uninformative ultrasound in black vs white women
- Trial name
- NCT06293066
- Testing
- Ultrasound
- Where
- United Kingdom
- Volunteers
- 330 people
- Sponsor
- King's College Hospital NHS Trust
Cervical Cancers
Sentinel Lymph Node (SLN) Mapping with Charcoal Carbon Dye in Early Stage Cervical Cancer
The aim of the present study is to compare the efficacy of charcoal carbon dye (CCD) in sentinel lymph node mapping compared to indocyanine green (ICG) mapping regarding detection rates, sensitivity, specificity, negative and…
- Trial name
- SLN (NCT06697054)
- Testing
- Sentinel node biopsy with either ICG or carbon dye injection to cervix
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul University
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Endometrial Cancer
Advancing Risk Stratification in Endometrial Cancer
The DaPHNE study is an observational, ambispective, multicenter study designed to evaluate whether the integration of circulating tumor DNA (ctDNA) and plasma proteomic profiling with the 2023 FIGO staging system improves…
- Trial name
- DaPHNE (NCT07746024)
- Testing
- Liquid Biopsy
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ovarian Cancer, Cervical Cancer
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
The purpose of this study is evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of of fully human anti - VEGF monoclonal antibody LY00101 and explore the potential prognostic and predictive…
- Conditions
- Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer
- Trial name
- NCT03644459
- Testing
- LYN00101
- Sponsor
- Lynkcell Inc.
Cervical Cancer
Evaluation of the Cancer Tracking System (CATSystem)
Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent…
- Trial name
- CATSystem (NCT06286462)
- Testing
- Cancer Tracking System (CATSystem)
- Where
- 10 sites in Kenya
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center